In pre-clinical models, TP53 deficient AML uniquely exhibits intrinsic resistance to CAR-T mediated cytotoxicity due to prolonged immune synapse formation that paradoxically induces T-cell exhaustion and diminishes effector function [208,209]. The gene discussed is TP53; the disease is acute myeloid leukemia.